Key Information
Source
summary/abstract
Treatments have evolved for transthyretin amyloid cardiomyopathy (ATTR-CM)external link, opens in a new tab, which occurs when a protein called transthyretin changes shape and builds up in the heart. Instead of simply addressing symptoms, newer and future treatments target the underlying cause of ATTR-CM and can slow the disease.